AUSTRALASIA

Australia is the third largest region by revenue contribution, supported by strong sales teams promoting a diversified portfolio of prescription, OTC and consumer health products. Aspen’s production facilities are also one of the largest manufacturing sites in Australia, with an ability to produce tablets, liquids and semi-solids.

Key Countries

Australia,
New Zealand

The Australian pharmaceutical sector was valued at USD13,2 billion as at MAT
August 2020.
Aspen was ranked fourth by volume in the Australian pharmaceutical sector
for the period ended 31 August 2020, and first among non-generic suppliers.
Aspen’s overall sales representation performance rankings MAT June 2020 shows
continued improvement and a sustained number one position.

Source: IQVIA – August 2020

STATISTICS

Number of products launched:

2

(2019: 4)

Average staff turnover*:

9%

(2019: 10%)

Number of product recalls:

2

(2019: 1)

Number of work-related fatalities:

Nil

(2019: Nil)

* Rate excludes employees transferred in Nutritionals disposal.

Number of permanent employees

531

June 2020

515

June 2019

Revenue	2020 R’million	2019 (CER) R’million	Change %
Regional Brands	3 546	3 480	2
Sterile Focus Brands	683	709	(4)
Anaesthetics Brands	665	686	(3)
Thrombosis Brands	18	23	(22)

Total Commercial Pharmaceuticals	4 229	4 189	1
Manufacturing – FDF	393	378	4
Total	4 622	4 567	1